Jeremy Cetnar

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

Alice T. Shaw, Leena Gandhi, Shirish M. Gadgeel et al. · The Lancet Oncology · 2015 · 638 citations · Full text

Medicine, Oncology, Pharmacology +13

Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer

Julie N. Graff, Joshi J. Alumkal, Charles G. Drake et al. · Oncotarget · 2016 · 360 citations · Full text

Medicine, Oncology, Pharmacology +8

Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study

Fiona Blackhall, Kevin Jao, Laurent Greillier et al. · Journal of Thoracic Oncology · 2021 · 258 citations · Full text

Medicine, Oncology, Pharmacology +16

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)

Dara L. Aisner, Lynette M. Sholl, Lynne D. Berry et al. · Clinical Cancer Research · 2017 · 218 citations · Full text

Medicine, Genetics, Oncology +16

Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance

Joshi J. Alumkal, Duanchen Sun, Eric Lu et al. · Proceedings of the National Academy of Sciences · 2020 · 169 citations · Full text

Medicine, Oncology, Pharmacology +17